Research achieving 97% sustained virologic response using a new medication with generic sofosbuvir, presented at the International Liver Congress 2018.
CorporatePharco Pharmaceuticals, a leading pharmaceutical company, and Alameda Healthcare Group, a prominent healthcare provider, have signed a strategic Memorandum of Understanding (MoU) to collaborate on patient support, disease awareness, and scientific and medical education, with a focus on chronic disease care.
CorporateAdwaya Pharco International, Pharco’s arm in Saudi Arabia, signed an S&L agreement with Shilpa Pharma Lifesciences during CPHI Milan 2026. The agreement provides access to an innovative technology intended to strengthen the company’s capabilities and support its continued growth in the Saudi market.
CorporatePharco Pharmaceuticals signed a Memorandum of Understanding with Baheya Hospitals to strengthen cooperation in oncology care and support the development of healthcare services. The signing took place in the presence of Dr. Sherine Helmy, Chairman and CEO of Pharco Pharmaceuticals.
For interview requests, image assets, or fact-checks, please contact our communications team directly.